Effects of Antiplatelet and Antioxidant Agents on Drusen Progression: A Pilot, Prospective Cohort Study

Effects of Antiplatelet and Antioxidant Agents on Drusen Progression: A Pilot, Prospective Cohort Study

The aim of this clinical trial is to evaluate the effect of low doses of antiplatelet medications (aspirin 81 mg/day or clopidogrel 75 mg/day) with or without a combination of antioxidants (N-acetylcysteine 600 mg/day) in a dry AMD patient with large drusen.

Participants will divided in to three groups.

• Participants who were already taking low dose antiplatelet medications.
• Participants who take the antiplatelet drug mentioned above in addition to the antioxidant prescribed by the investigator
• Participants does not use any medications.

Inclusion Criteria:

• Dry AMD with at least 1 large drusen. According to the AREDS study, large drusen have a size of more than 125 micron.
• Patients can evaluate SD-OCT (Spectral domain optical coherence tomography), OCT angiography, and best-corrected visual acuity.
• Age range: 50-85 years
• Patients who have previously used antiplatelet drugs.

Exclusion Criteria:

• Patient with advanced AMD, such as geographic atrophy, neovascular complications (choroidal neovascularization)
• Patient with additional retinal diseases that affect visual acuity, e.g., retinal detachment, diabetic macular edema.
• Patient with a history of intravitreal anti-VEGF injection or macular laser.
• Patient using SSRIs, SNRIs, azole, NSAIDs, dual antiplatelet, anticoagulant medications.